Change Language

Select Language

Global Telmisartan Market to Reach US$ 4.4 Billion by 2027, Propelled by the Significant Growth in the Pharmaceutical Industry

Published on Sep 15, 2022

The latest report by IMARC, titled “Telmisartan Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, finds that the global telmisartan market size reached US$ 3.5 Billion in 2021. Telmisartan refers to an angiotensin receptor blocker (ARB) that works by blocking a chemical in the human body that tightens blood vessels. It is also primarily used for the treatment of hypertension and cardiovascular risk reduction. It is used alone as well as in combination with several other agents, including amlodipine and hydrochlorothiazide. Nowadays, it is generally available in the form of tablets and oral oil suspension variants and is dispensed with other medications to improve its efficacy. It also helps in relaxing the blood vessels and promoting kidney function. In recent years, telmisartan has gained traction with the rising number of individuals diagnosed with various chronic illnesses.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of the associated industries. These observations will be integrated into the report.

Global Telmisartan Market Trends:

One of the primary factors driving the market is the significant growth in the pharmaceutical industry. Additionally, the increasing incidences of diabetes, high blood pressure, and numerous kidney-related disorders are creating a positive market outlook. Other than this, telmisartan assists in modifying genes for insulin sensitization, regulating glucose and lipid metabolism, and managing chronic diabetic kidney disease and other disorders. This, coupled with the increasing marketing approvals for generic versions of telmisartan, is propelling the market growth. Besides this, the rising research on telmisartan drugs in emerging nations is escalating the product demand. Furthermore, extensive investment in research and development (R&D) activities by key players to advance telmisartan medications for the treatment of diabetic nephropathy is creating for a favorable market outlook. Other growth-inducing factors include improvements in healthcare infrastructure, rising geriatric population, and increasing number of individuals leading sedentary lifestyles. Looking forward, IMARC Group expects the market value to reach US$ 4.4 Billion by 2027, expanding at a CAGR of 4.1% during the forecast period (2022-2027).

Market Summary:

  • Based on the indication, the market has been bifurcated into hypertension and cardiovascular risk reduction.
  • On the basis of the distribution channel, the market has been divided into hospital pharmacies, drug stores and retail pharmacies, and online stores.
  • Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals pls, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.), and Torrent Pharmaceuticals Ltd.


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

USA: +1-631-791-1145
Follow us on twitter : @imarcglobal


Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )

Drop us an email at